Latest News and Press Releases

Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.

Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.

Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.

Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.

Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.

CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.